Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Olympus jumps through final anti-trust hoops for Gyrus acquisition

This article was originally published in Clinica

Executive Summary

Olympus' proposed £935m ($1.8bn) acquisition of UK firm Gyrus has received the go-ahead from anti-trust authorities in Germany and Austria. In addition to the US approval gained in December 2007, the transaction has cleared all the required anti-trust hurdles. Gyrus, which specialises in minimally-invasive surgery, agreed to be acquired by Japanese group Olympus in November for £6.30 per share (see Clinica No 1283, p 1).

You may also be interested in...



Japanese Firms Pursued Over Edirol Ingredient

Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.

Who’s Hired? Apotex Names New US President & CEO

As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles. 

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel